GlassScriptPhysician profile
James Kalyvas
NPI 1811151772
$5,571.26
in general payments reported to CMS, 2019-2025
12 companies · $93.38 in 2025
The $93.38 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $900 · 2021: $436 · 2022: $430 · 2023: $1,535 · 2024: $400 · 2025: $93.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019 · Travel and Lodging: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.51 |
| Travel and Lodging | $1,010.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,296.07 | 2019 | |
| Medtronic, INC. | $1,190.30 | 2023-2025 | Mazor X System |
| Depuy Synthes Sales INC. | $1,138.06 | 2019-2025 | Fibergraft Bg Morsels, Sentio, Conduit |
| Medical Device Business Services, INC. | $900.00 | 2020 | |
| Globus Medical, INC. | $479.21 | 2019-2023 | Creo 5.5 |
| Providence Medical Technology, INC. | $205.97 | 2022-2023 | |
| Wenzel Spine, INC. | $170.63 | 2023 | Varilift |
| Boston Scientific Corporation | $111.52 | 2019 | |
| Aesculap, INC. | $30.88 | 2019 | |
| Stryker Corporation | $30.64 | 2019 | |
| Davol INC. | $17.98 | 2025 | Channel Drain |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$40,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kalyvas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.